Novel agents in relapsed/refractory diffuse large B-cell lymphoma

被引：8

作者：

Varma, Gaurav ^{[1
]}

Goldstein, Jordan ^{[2
]}

Advani, Ranjana H. ^{[2
,3
]}

机构：

[1] NYU, Dept Med, Div Hematol & Med Oncol, Grossman Sch Med, New York, NY USA

[2] Stanford Univ, Dept Med, Div Oncol, Stanford, CA USA

[3] Stanford Canc Inst, Lymphoma, 875 BlakeWilbur Dr, Stanford, CA 94305 USA

来源：

HEMATOLOGICAL ONCOLOGY | 2023年 / 41卷

关键词：

DLBCL; novel agents; relapsed; refractory; NON-HODGKIN-LYMPHOMA; POLATUZUMAB VEDOTIN; SINGLE-ARM; OPEN-LABEL; BRENTUXIMAB VEDOTIN; CD30; EXPRESSION; LENALIDOMIDE; RITUXIMAB; MULTICENTER; SAFETY;

D O I：

10.1002/hon.3143

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), ineligible for or relapsing after autologous stem-cell transplant or chimeric antigen-receptor T-cell therapies have poor outcomes. Several novel agents, polatuzumab vedotin, tafasitamab, loncastuximab tesirine, and selinexor, have been approved and offer new opportunities for this difficult to treat population. Studies are evaluating combination of these agents with chemotherapy and other emerging therapies. Additionally, advances in our understanding of DLBCL biology, genetics, and immune microenvironment have allowed for the identification of new therapeutic targets like Ikaros and Aiolos, IRAK4, MALT1, and CD47 with several agents in ongoing clinical trials. In this chapter we review updated data supporting the use of the approved agents and discuss other emerging novel therapies for patients with R/R DLBCL.

引用

页码：92 / 106

页数：15

共 106 条

[11] Planned Interim Analysis of a Phase 2 Study of Loncastuximab Tesirine Plus Ibrutinib in Patients with Advanced Diffuse Large B-Cell Lymphoma (LOTIS-3) [J].

Carlo-Stella, Carmelo ;

Zinzani, Pier Luigi Luigi ;

Janakiram, Murali ;

Dia, Vivian ;

He, Xiaomin ;

Ervin-Haynes, Annette ;

Depaus, Julien .

BLOOD, 2021, 138

[12] Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier [J].

Carpio, Cecilia ;

Bouabdallah, Reda ;

Ysebaert, Loic ;

Sancho, Juan-Manuel ;

Salles, Gilles ;

Cordoba, Raul ;

Pinto, Antonio ;

Gharibo, Mecide ;

Rasco, Drew ;

Panizo, Carlos ;

Lopez-Martin, Jose A. ;

Santoro, Armando ;

Salar, Antonio ;

Damian, Silvia ;

Martin, Alejandro ;

Verhoef, Gregor ;

Van den Neste, Eric ;

Wang, Maria ;

Couto, Suzana ;

Carrancio, Soraya ;

Weng, Andrew ;

Wang, Xuehai ;

Schmitz, Frank ;

Wei, Xin ;

Hege, Kristen ;

Trotter, Matthew W. B. ;

Risueno, Alberto ;

Buchholz, Tonia J. ;

Hagner, Patrick R. ;

Gandhi, Anita K. ;

Pourdehnad, Michael ;

Ribrag, Vincent .

BLOOD, 2020, 135 (13) :996-1007

[13] CC-99282 is a Novel Cereblon (CRBN) E3 Ligase Modulator (CELMoD) Agent with Enhanced Tumoricidal Activity in Preclinical Models of Lymphoma [J].

Carrancio, Soraya ;

Groocock, Lynda ;

Janardhanan, Preethi ;

Jankeel, Diana ;

Galasso, Ryan ;

Guarinos, Carla ;

Narla, Rama K. ;

Groz, Matthew ;

Leisten, Jim ;

Pierce, Daniel W. ;

Rolfe, Mark ;

Lopez-Girona, Antonia .

BLOOD, 2021, 138

[14] Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study [J].

Crump, Michael ;

Neelapu, Sattva S. ;

Farooq, Umar ;

Van den Neste, Eric ;

Kuruvilla, John ;

Westin, Jason ;

Link, Brian K. ;

Hay, Annette ;

Cerhan, James R. ;

Zhu, Liting ;

Boussetta, Sami ;

Feng, Lei ;

Maurer, Matthew J. ;

Navale, Lynn ;

Wiezorek, Jeff ;

Go, William Y. ;

Gisselbrecht, Christian .

BLOOD, 2017, 130 (16) :1800-1808

[15] Frequent copy number variations of PI3K/AKT pathway and aberrant protein expressions of PI3K subunits are associated with inferior survival in diffuse large B cell lymphoma [J].

Cui, Wenli ;

Cai, Ying ;

Wang, Weige ;

Liu, Zebing ;

Wei, Ping ;

Bi, Rui ;

Chen, Weixiang ;

Sun, Menghong ;

Zhou, Xiaoyan .

JOURNAL OF TRANSLATIONAL MEDICINE, 2014, 12

[16] A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma [J].

Czuczman, Myron S. ;

Trneny, Marek ;

Davies, Andrew ;

Rule, Simon ;

Linton, Kim M. ;

Wagner-Johnston, Nina ;

Gascoyne, Randy D. ;

Slack, Graham W. ;

Brousset, Pierre ;

Eberhard, David A. ;

Hernandez-Ilizaliturri, Francisco J. ;

Salles, Gilles ;

Witzig, Thomas E. ;

Zinzani, Pier Luigi ;

Wright, George W. ;

Staudt, Louis M. ;

Yang, Yandan ;

Williams, P. Mickey ;

Lih, Chih-Jian ;

Russo, Jacqueline ;

Thakurta, Anjan ;

Hagner, Patrick ;

Fustier, Pierre ;

Song, Dale ;

Lewis, Ian D. .

CLINICAL CANCER RESEARCH, 2017, 23 (15) :4127-4137

[17]

de Vos S., 2022, BLOOD, V140, P6635, DOI [10.1182/blood-2022-162447, DOI 10.1182/BLOOD-2022-162447]

[18] Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma [J].

Dickinson, Michael ;

Briones, Javier ;

Herrera, Alex F. ;

Gonzalez-Barca, Eva ;

Ghosh, Nilanjan ;

Cordoba, Raul ;

Rutherford, Sarah C. ;

Bournazou, Eirini ;

Labriola-Tompkins, Emily ;

Franjkovic, Izolda ;

Chesne, Evelyne ;

Brouwer-Visser, Jurriaan ;

Lechner, Katharina ;

Brennan, Barbara ;

Nueesch, Eveline ;

DeMario, Mark ;

Ruettinger, Dominik ;

Kornacker, Martin ;

Hutchings, Martin .

BLOOD ADVANCES, 2021, 5 (22) :4762-4770

[19]

Diefenbach C., 2021, HEMATOL ONCOL, V39, DOI [10.1002/hon.155_2880, DOI 10.1002/HON.155_2880]

[20]

Diefenbach C., 2021, HEMATOL ONCOL, V39, DOI [10.1002/hon.154_2880, DOI 10.1002/HON.154_2880]

← 1 2 3 4 5 6 7 8 9 10 →